Renowned Speakers

Giulio Tarro

President, Foundation de Beaumont Bonelli for cancer research Italy

Theresa I. Dale

Founder & Dean, California College of Natural Medicine USA

Ananda M. Chakrabarty

Scientist and Professor, University of Illinois at Chicago Illinois USA

Helieh Oz

Investigator, University of Kentucky Medical Center USA

K. M. Yacob

Marma Heatth Centre India

Durgesh Sinha

Temple University, Philadelphia USA

Recommended Global Infectious Diseases Conferences

Flu and Infectious Diseases 2018

About Conference

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Flu 2016, Conference Series llc LTD is delighted to announce the next event

Conference Series llc LTD invites all the participants from all over the world to attend 3^rd International Conference on Flu & Emerging Infectious Diseases: Control & Prevention during November 07-08, 2018 at Alabama, USA.

The field of Flu & Emerging Infectious Diseases: Control & Prevention is growing rapidly and its development is making tremendous impacts in medical sciences and pharmaceuticals. The importance and significance can be gauged by the fact that it has made huge advancements over the course of time and is continuing to influence various sectors.

World Flu & Emerging Infectious Diseases: Control & Prevention 2018

Opportunity to attend the presentations delivered by eminent scientists from all over the world. Selected contributions will be published in following Conference Series Journals

· Virology & Mycology

· Virology & Antiviral Research

· Journal of Vaccines & Vaccination

Participation in sessions on specific topics on which the conference is expected to achieve progress

Global networking: In transferring and exchanging Ideas

Conference brings together Scientific Researchers, Virologists, Immunologists, Microbiologists, Pathologists, Infectious Diseases Specialists, Health Care Professionals and Physicians

Sessions/Tracks

Track 1: Emerging Infectious Diseases

Infectious disease whose incidence in human has increased in the past 2 decades (or) threatens to be in the near future have been defined as "Emerging". These diseases include new infections, previously no recognized infections and old infections reappearing due to antimicrobial resistance and public health issues due to unhygienic conditions.

Related Conference

3^rd Annual Congress on Rare Diseases and Orphan Drugs October 30-November 1, 2017 San Antonio, Texas, USA, 13th World Congress on Infection Prevention and Control Dec 14-15, 2017 Rome, Italy, 5^th International congress on Infectious Diseases March 1-2, 2018 Berlin, Germany, 7^th International Conference on Bacteriology and Infectious Diseases May 21-22, 2018 Osaka, Japan, 6^th International Congress on Bacteriology and Infectious Diseases May 21-22, 2018 New York, USA, 4^th World Congress on Rare Diseases and Orphan Drugs June 11-12, 2018 Dublin, Ireland, 4^th International Conference on Influenza and Zoonotic Diseases July 2-3 2018 Vienna, Austria, 3^rd International Conference on Infection Control September 17-18, 2018 San Diego, USA, 4^th International conference on Flu & Emerging Infectious Diseases September 17-18, 2018 San Diego, USA.

4^th Annual Microbiology & Infectious Diseases Asia Congress 2017 October 10-11, 2017 Singapore, Infectious Diseases in Primary Care Oct 25-27, 2017, Fairmont Copley Plaza, Boston, MA, 2^nd Gulf Congress of Clinical Microbiology and Infectious Diseases 2017 (GCCMID 2017) November 1-4, 2017, Gulf Hotel and Exhibition Centre Manama , Pediatric Infectious Diseases: A Primary Care and Hospitalist Approach January 15-19, 2018 , Hyatt Regency Sarasota, 10^th Annual All-Russian Congress on Infectious Diseases February 26-28, 2018, Radisson Slavyanskaya Hotel.

Track 2: Global Distribution and Transmission of Emerging infectious disease

The extent of the global burden of infectious diseases depends on the already prevailing incidences and prevalence’s of familiar infections together with the consistent, but uneven, flow of emerging and remerging infections. Infectious diseases emerging throughout history have included some of the most dangerous plagues of the past. As new infections continue to emerge today, while many of the old plagues are still with us. Infectious disease can be transmitted by person to person by direct or indirect contact where Micro-organisms, viruses, fungi and parasites are most common source of transmission.

Related Conference

9th International Conference on Emerging Infectious Diseases August 27-28, 2018 Zurich, Switzerland, 20^th International Conference on Emerging Infectious Diseases February 15-16, 2018 London, United Kingdom, International Conference on Emerging Infectious Diseases August 26-29, 2018 Atlanta, Georgia, Global Experts Meeting On Infectious Diseases August 13-14, 2018 Tokyo, Japan.

Track 3: Factors In The Emergence Of Infectious Diseases

Most of the emerging infections appear to be caused by pathogens already present in the environment, brought out of obscurity or given a selective advantage by changing conditions and afforded an opportunity to infect new host populations. The process by which infectious agents may transfer from animals to humans or disseminate from isolated groups into new populations can be called microbial traffic. A number of activities increase microbial traffic and as a result promote emergence and epidemics.

Related Conference

3^rd International Conference on Flu and Emerging Infectious Diseases 2017 November 6-7, 2017 Hampton Inn Tropicana, Las Vegas, NV, United States Global Experts Meeting On Infectious Diseases August 13-14,2018 Tokyo, Japan, 8tth Edition of International Conference on Infectious Diseases June 07-08, 2018 London, UK, 16^th Annual Meeting on Influenza March 28-29, 2018 Orlando, USA.

Track 4: Host Defences against Infectious Diseases

For preventing infectious diseases the human body has several general mechanisms. Some of these mechanisms are referred to as nonspecific defences because they operate against a wide range of pathogens. Some of the other mechanisms are referred to as specific defences because they target particular pathogens and pathogen-infected cells.

Related Conference

8^th International conference on Infectious and Inflammatory Diseases May 21-22, 2018 Vienna, Austria, 8th European Neurology Congress 21 Sep 2016 - 23 Sep 2019 Amsterdam, Netherlands, 2^nd Gulf Congress of Clinical Microbiology and Infectious Diseases 2017 (GCCMID 2017) November 1-4, 2017, Gulf Hotel and Exhibition Centre Manama.

Track 5: Public Health Measures to Prevent Emerging Infectious Diseases

Developed countries have regulations that help to protect the general public from infectious diseases. Public health measures typically involve eliminating the pathogen from the reservoir or from its route of transmission. The measures include ensuring a safe water supply, effectively managing sewage treatment and disposal, and initiating food safety, animal control, and vaccination programs.

Related Conference

Emerging and Re-emerging Viruses October 1-3,2017 Arlington, VA, USA, 18^th International Congress on Infectious Diseases March 1-4, 2018 Buenos Aires, Argentina, 16^th Annual Meeting on Influenza March 28-29, 2018 Orlando, USA. Pediatric Infectious Diseases: A Primary Care and Hospitalist Approach January 15-19, 2018.

Track 6: Treatment for Emerging Infectious Diseases

The word “Antibiotic” has become the most commonly used word to refer to a chemical substance used to treat bacterial infections. The term "antimicrobial" usually refers to anything that prevents the growth of microbes. Technically, the term antimicrobial does not encompass the "anthelminthic" drugs because parasitic worms are not microscopically small. Antimicrobials can be either microbistatic or microbicidal.

Related Conference

10^th European Congress on Tropical Medicine and International Health October 16 - 20 2017 Antwerpen, Belgium, AAFP — 2017 AAFP Conference - Feline Infectious Diseases & Pediatrics October 19 -22 2017 Denver, CO, United States, Infectious Diseases in Primary Care October 25 – 27, 2017Boston, United States, 22^nd Edition of International Conference on Immunology and Evolution of Infectious Diseases May 10-12, 2018, Frankfurt, Germany.

Track 7: Flu /Influenza Virus

Influenza viruses are among the most common causes of human respiratory infections, and are also among the most significant because they cause high morbidity and mortality. Influenza outbreaks have apparently occurred since at least the middle Ages. In the elderly, in infants, and in people with chronic diseases, influenza is associated with especially high mortality. In the United States, flu results in approximately 200,000 hospitalizations and 36,000 deaths in a typical endemic season.

Related Conference

World Congress on Virology, Bacteriology & Infectious Diseases, October 25-27, 2018 Birmingham, UK, United States Global Experts Meeting On Infectious Diseases August 13-14,2018 Tokyo, Japan, , Infectious Diseases in Primary Care October 25 – 27, 2017Boston, United States, Annual Meeting on Influenza March 28-29, 2018 Orlando, USA.

Track 8: Antigenic Variation of Flu/ Influenza Virus

The explosive nature of epidemic flu and the specific clinical features of this disease have given definitive epidemiological records of this infection since the beginning of the nineteenth century. Some of the epidemics were recorded during the nineteenth century but the first pandemic was not precisely recorded until 1889-92. A second pandemic, probably originating in Europe, occurred in 1918-19, and is called as Spanish Influenza. It is responsible for 20-25 million deaths, principally in young adults. It was suggested that this strain had unusual virulence.

Related Conference

Track 9: Pathology of Flu/ Influenza Virus

When flu virus is driven into the respiratory tract by aerosol or by contact with saliva or other respiratory secretions from an affected individual, it attaches and replicates in epithelial cells. The virus replicates in cells of both the lower and upper respiratory tract. Viral replication combined with the immune response to infection lead to destruction and loss of cells lining the respiratory tract.

Related Conference

Track 10: Symptoms and Treatment Of Flu/Influenza Virus

There are three types of influenza viruses affect people, called Type A, Type B, and Type C. Approximately 33% of people with influenza are asymptomatic. The symptoms of influenza can start quite suddenly one to two days after infection. Fever and extreme coldness , Cough, Nasal congestion, Vomiting, Runny nose, Sneezing, Body aches, especially joints and throat, Fatigue, Headache, skin (especially face), Petechial rash. People with the flu are advised to medications such as acetaminophen (paracetamol) to relieve the fever and muscle aches associated with the flu. Antiviral medication may be effective, if given early, but some strains of influenza can show resistance to the standard antiviral drugs.

Related Conference

Track 11: Flu/ Influenza Vaccines And Vaccination

The first and foremost efforts to develop influenza vaccines were initiated soon after influenza A and B viruses were identified as the etiologic agents of clinical influenza. The United States in 1945 has approved the first commercial vaccines using whole-inactivated influenza virus for use . The flu vaccine is an annual vaccination using a vaccine to protect against the highly variable influenza virus that is specific for a given year. Risk management and effectiveness of vaccines are important for public health.

Related Conference

Track 12: Flu/ Influenza Vaccines and Vaccination

Influenza vaccines, also known as flu shots or jabs, are vaccines that protect against influenza. A new version of the vaccine is developed twice a year as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. The World Health Organization (WHO) and Centres for Disease Control and Prevention (CDC), The European Centre for Disease Prevention and Control recommends yearly vaccination for nearly all people over the age of six months, especially those at high risk.

Related Conference

Track 13: Antivirals and Therapeutics for Flu disease

Antiviral drugs are prescription medicines that fight against the flu in your body. The two classes of antiviral drugs used against influenza are neuraminidase inhibitors (oseltamivir and zanamivir) and M2 protein inhibitors (adamantine derivatives). Food and Drug Administration (FDA) and European Agency for the Evaluation of Medicinal Products (EMEA), now a days force developers as well as manufacturers to improve their production and purification processes for viral vectors and vaccines.

Related Conference

Track 14: Flu Vaccines and Case Reports of Flu

Influenza drug effectivity is evaluated in clinical trials conducted within the setting of current, naturally occurring influenza illness. However, a drug effective within the treatment of seasonal influenza might not be effective or as effective in pandemic influenza or in sporadic cases caused by alternative novel strains. Avian influenza, listed by the World organisation for Animal Health (OIE), has become a illness of nice importance for animal and human health.

Related Conference

Track 15: Flu Virus -Advancements in Detection & Differentiation

Influenza outbreaks and epidemics constitute on-going risks to global human public health. Recently, human infections with A/H5N1 avian influenza viruses have intensified the potential for the emergence of an influenza A virus with pandemic potential. Laboratory identification of human influenza virus infections is commonly performed using virus isolation in cell culture, direct antigen detection, or detection of influenza-specific RNA by reverse transcriptase-polymerase chain reaction (RT-PCR). In recent years commercial influenza rapid diagnostic tests have become available which are antigen detection tests that produce results within 30 minutes. They can provide results in a clinically relevant time frame to complement the use of antiviral medications for treatment and chemoprophylaxis of influenza.

Related Conference

Track 16: Epidemology and Public Health of Flu/ Influenza

Public health epidemiologic investigations and surveillance are critical public health functions for identifying threats to the health of a community. In an emergency, public health surveillance is the on-going systematic collection, analysis, interpretation, and management of public health-related data to verify a threat or incident of public health concern, and to characterize and manage it effectively through all phases of the incident. Surveillance data is used to identify and monitor the arrival of influenza, its geographic spread, intensity of activity, characteristics of those infected, as well as severity and changing trends in order to guide prevention and control recommendations.

Related Conference

Market Analysis Report

Importance & Scope:

Flu is an infectious disease caused by the influenza virus. Influenza is a highly contagious disease affecting almost all mammals and birds. Flu occurs globally with an annual attack rate estimated at 5%–10% in adults and 20%–30% in children. Illnesses can result in hospitalization and death mainly among high-risk groups (the very young, elderly or chronically ill). Worldwide, these annual epidemics are estimated to result in about 3 to 5 million cases of severe illness, and about 250 000 to 500 000 deaths.

Experts from various fields like virology, medicine, immunology, microbiology, public health planning, epidemiology, pharmacology and vaccinology all work on the flu virus.

The infectious diseases therapeutic market in US is estimated to grow at a rate of 3.37% between 2014- 2019. As per the records, 25% of deaths are mainly due to infectious diseases globally. Current market trend shows that North America has the more global market for infectious diseases therapeutics due to increasing incidence of infectious diseases and due to rise in aging population. Followed by North America highest global market is expected in Asia then followed by the Europe in the global infectious diseases therapeutics market.

USA

CDC monitors the hospitalizations associated with laboratory-confirmed influenza virus infections Among 9,586 cases with influenza type specified, 8,497 (88.2%) were associated with influenza A virus infection, 1,046 (10.9%) with influenza B virus infection, and 43 (0.4%) were associated with mixed influenza A and influenza B virus infections. Persons aged 18–64 years accounted for 57.4% of reported hospitalizations. The cumulative incidence for all age groups for the period October 1, 2013–April 30, 2014, was 35.6 per 100,000 (Figure 3). The cumulative hospitalization rate (per 100,000 population) by age group for this period was 46.9 (for 0–4 years), 9.5 (5–17 years), 22.0 (18–49 years), 54.3 (50–64 years), and 88.1 (≥65 years).

Market for Flu and Emerging Infectious Diseases Research:

The market is broken down into vaccines, therapeutics, and diagnostic products. The vaccines segment has the largest share of the market, worth an estimated $3.2 billion in 2009. This segment is expected to grow at a CAGR of 5.6% to reach nearly $4.2 billion in 2014. The therapeutics segment has the second-largest share of the market with $2.1 billion in 2009. But that segment is expected to decrease at a CAGR of -2.4%, falling to $1.9 billion in 2014. As many as 500,000 people die of influenza annually and with the threat of a pandemic, government agencies and disease-prevention organizations are devoted to gaining control of the situation.

The Infectious disease diagnostic (IDD) market is estimated to grow at a CAGR of 7.9% to reach $18,156.2 million by 2019. Traditional diagnostic techniques such as immunodiagnostics and biochemical characterization are the largest segments of the IDD market. However, molecular diagnostic techniques, such as microarrays and isothermal nucleic acid amplification technology (INAAT), will show the fastest growth in the forecast period.

Fund Allotment to Flu Research:

The US government awarded five-year contracts for more than $1 billion to five drug manufacturers developing technology for speedier mass production of vaccines in the event of a pandemic from the $3.8 billion pandemic preparedness bill passed in 2005. Currently, flu vaccines are produced in specialized chicken eggs, but that technique does not allow for speedy mass vaccinations." The companies receiving the contracts were:

GlaxoSmithKline $274.8 million
Medimmune Inc $169.5 million
Novartis Vaccines and Diagnostics $220.5 million
DynPort Vaccine Company,LLC $41 million
Solvay Pharmaceuticals $298.6 million

The US government purchased from Sanofi Pasteur and Chiron Corporation several million doses of vaccine in case of an influenza pandemic due to H5N1 and is conducting clinical trials on them. ABC News reported that Beginning in late 1997, the human trials have tested 30 different vaccines, all pegged to the H5N1 virus.

For H9N2 threat, NIAID contracted with Chiron Corporation to produce investigational batches of an inactivated vaccine, which will be evaluated clinically by NIAID early next year^.For H5N1, Aventis-Pasteur and Chiron are both producing investigational lots of inactivated H5N1 vaccine preparations additionally, DHHS has contracted with Aventis to produce up to 2 million doses to be stockpiled for emergency use, if needed, to vaccinate health workers, researchers, and, if indicated, the public in affected areas. Development and evaluation of a combination antiviral regimen against these potential pandemic influenza strains are also now under way.

According to Global Pandemic Influenza Preparedness Markets, their size, trends and drivers, principally for the countries with health expenditures per capita exceeding $2,000. The results of this study found that since outbreaks of bird flu in 2005 and swine flu in 2009, the governments had recognized antiviral pandemic stockpiling as their preferred strategy for disease containment and mitigation. Market Research Media has found that over the past five years, government spending worldwide on Pandemic Influenza Preparedness has more than tripled from $2.2 billion in 2004 to $7 billion in 2009, at a 17% CAGR. Market Research Media forecasts that worldwide government spending on Pandemic Influenza Preparedness will continue to grow, though at more moderate rate of a 5% CAGR, reaching almost $10 billion by 2015.

The HHS announces funding of about $1 billion for clinical studies that will take place over the next few months and for commercial-scale production of two potential vaccine ingredients for the pre-pandemic influenza stockpile.

The following companies will receive funding to produce H1N1 vaccine ingredients:

Novartis AG – $289 million,
Sanofi Aventis SA – $191 million,
GlaxoSmithKline PLC – $181 million,
Another $150 million will be directed to produce pilot lots of vaccine and to fund the clinical studies.

Reference:

Journals List

As per available reports about 14 journals, 90 Conferences, 70 workshops are presently dedicated exclusively to flu medicine and about 366282 articles are being published on the current trends in flu medicine. In terms of research annually, USA, India, Japan, Brazil and Canada are some of the leading countries where maximum studies related to flu medicine are being carried out. As reported in “Cytokines Network and Influenza Virus Infection” article, Influenza, commonly known as "the flu", is an infectious disease of birds and mammals caused by RNA viruses of the family Orthomyxoviridae, the influenza viruses.

Flu and Infectious Diseases

Infectious diseases are mostly caused by viruses, bacteria, fungi and protozoan parasites. Many of the infectious diseases are contagious and transmissible. They are epidemic and life threatening if untreated. Proper diagnosis and treatment should be adopted for prevention and transmission of infections. Currently research is going on new medications and new target proteins for effective treatment.

Related Journals of Flu and Infectious Diseases

Journal of Infectious Diseases & Therapy, Bacteriology Journal, Clinical Infectious Disease Journal, Immunology Journal, Neuroinfectious Disease Journal, Pathology Journal, Influenza and other Respiratory Viruses, Emerging Microbes and Infections, Surgical Infections, Viruses.

Influenza Diagnosis

A number of tests are performed to diagnose influenza. Viral culture for this respiratory sample is important to identify the influenza A subtypes and influenza A and B strains leading to illness. RIDTS (Rapid Influenza Diagnostic Test) is used to detect influenza virus in 15 minutes. Serologic testing for influenza needs paired acute and convalescent sera and these testing results for human influenza.

Related Journals of Influenza Diagnosis

Translational Medicine, Epidemiology: Open Access, Journal of Medical Microbiology & Diagnosis, Journal of Molecular Biomarkers & Diagnosis, Mycobacterial Diseases, Journal of Medical Diagnostic Methods, Journal of Infectious Diseases & Therapy, Journal of Cardiovascular Diseases & Diagnosis, JBR Journal of Clinical Diagnosis and Research, Influenza and other Respiratory Viruses, Clinical Infectious Diseases, Journal of Infectious Diseases, Emerging Infectious Diseases, Emerging Infectious Diseases Journals

Flu Diagnosis

A number of tests are available to detect influenza viruses. Most commonly practised is “rapid influenza diagnostic tests”. Apart from rapid test there are more specific and accurate flu tests available to diagnose the presence of influenza virus. However all rapid test provide better result for detecting flu in children and adults.

Related Journals of Flu Diagnosis

Journal of Medical Diagnostic Methods, Journal of Bioterrorism & Biodefense, Journal of Medical Microbiology & Diagnosis, Journal of Emerging Infectious Diseases, RelJournal of Swine Health and Production, Advances in Influenza Research, Journal of Antivirals & Antiretroviral sated Journals of Swine flu diagnosis.

Flu and Infectious Diseases Journals Impact Factors List :

Journal Name	Journal Impact Factor*	Citations Report
Journal of Infectious Diseases & Therapy	1.65	Citations Report
Journal of Antivirals & Antiretrovirals	1.55 2.71 (5 Yr Journal Impact Factor)	Citations Report
Journal of Immunological Techniques & Infectious Diseases	0.214	Citations Report
Journal of Neuroinfectious Diseases	0.77 0.86 (5 Yr Journal Impact Factor)	Citations Report
Virology & Mycology	0.88 0.9 (5 Yr Journal Impact Factor)	Citations Report
Journal of AIDS & Clinical Research	1.64 3.69 (5 Yr Journal Impact Factor)	Citations Report
Biology and Medicine	1.44 2.93 (5 Yr Journal Impact Factor)	Citations Report
Journal of Bacteriology & Parasitology	0.71 3.01 (5 Yr Journal Impact Factor)	Citations Report
Journal of Community Medicine & Health Education	1.73 2.15 (5 Yr Journal Impact Factor)	Citations Report
Mycobacterial Diseases	0.93 0.29 (5 Yr Journal Impact Factor)	Citations Report
Journal of Medical Microbiology & Diagnosis	0.49 1.14 (5 Yr Journal Impact Factor)	Citations Report
Journal of Immunological Techniques & Infectious Diseases	0.214	Citations Report
Journal of Food & Industrial Microbiology	0.111	Citations Report
Journal of Neuroinfectious Diseases	0.77 0.86 (5 Yr Journal Impact Factor)	Citations Report
Journal of Tropical Diseases & Public Health	1.83 1.43 (5 Yr Journal Impact Factor)	Citations Report

Visa Information

Issue with VISA!!

Are you planning to have a professional and delightful trip to Birmingham, Alabama, USA???

We believe you must be having a query regarding your Visa to Visit as a Speaker/Delegate, Tourist or Business Person at Alabama, USA. Flu and Infectious Diseases Committee will be happy to help you in all regards to plan your trip to Alabama, USA. Here is the simplest way to know the process for your Visa Approval. Kindly drops us an email at: [email protected] Avail the official invitation letter from us to attend this event ahead with a closer step for approval of your VISA. Processing time for visa applications vary depending on the office and the time of the year. Delegates/Attendees are encouraged to submit their visa applications well in advance of the date of the event at a Visa Application Centre or on-line E-applications, including all supporting documents.

Letter of Invitation

It's the delegate's responsibility to investigate the visa requirements for USA and to apply for a visa, if necessary. Individuals requiring an Official Letter of Invitation from the conference organizers can request one by email by writing to us at [email protected] ; [email protected]

To receive a Letter of Invitation, delegates, accompanying persons/children, student/post-doc/youth delegates and exhibitors must first register for the conference.

The registration fee minus a handling fee of USD 100 will be refunded after the conference if the visa was applied for in time and proof is shown that a visa could not be granted even though all requested documents were submitted. Refund requests must be made in writing and sent to the Flu and Emerging Infectious Disease 2018 via email.

All expenses incurred in relation to the conference are the sole responsibility of the delegate. The Letter of Invitation does not guarantee an entry visa to USA. However, the conference organizers will not directly contact embassies and consulates on behalf of delegates.

The deadline for requesting a Letter of Invitation is one month before travelling to USA.

Past Conference Report

Flu-2015

International Conference on Flu (Flu-2015) was convened by OMICS International during June 08-10, 2015 at DoubleTree by Hilton Hotel Chicago-North Shore, USA. The meeting brought together a group of clinicians, virologists and industry representatives with interest and expertise in the field of influenza research. The three day program witnessed thought provoking keynote and plenary presentations from experts in the field of virology, immunology and microbiology, highlighting the theme, “Advanced Research in Flu".

Flu-2015 Organizing Committee would like to thank the Moderator of the conference, Dr. Rupert Beale, University of Cambridge, UK who contributed a lot for the smooth functioning of this event.

In the opening remark welcome note was given by Dr. Scott Umlauf, the support was extended by Honorable guests and Keynote Speakers of Flu-2015:
Scott Umlauf, VaxInnate Corporation, USA
Vadim Bichko ChemDiv, Inc, USA
Joshua DiNapoli, Sanofi Pasteur Biologics LLC, USA
Rangaraj Selvarangan, Children’s Mercy Hospitals and Clinics, USA
Ming Zhang, University of Georgia, USA.

The conference proceedings were carried out through various Scientific-sessions and plenary lectures. Also the conference was featured with Workshop and Symposium.

Workshop: A workshop on “Designing effective flu vaccines against a broad- spectrum of influenza viruses” organized by Dr. Pamuk Bilsel, FluGen Inc USA.

Symposium: A symposium on “Novel jet injection technology for influenza vaccination” organized by Dr. Chris Cappello, PharmaJet Inc, USA and Charles A Altman, bioCSL, USA.

We would like to thank the Poster Competition Judge Scott Umlauf, VaxInnate Corporation,USA for his valuable time. On behalf of the conference OMICS International,, congratulates the Best Poster awardees for their outstanding performance and appreciates all the participants who put their efforts in poster presentations and sincerely wishes them success in future endeavors.

Best Poster Winners:

Janice Koshy, Baylor Scott & White Infectious Diseases Department, USA
Harshini Ashar, Oklahoma State University, USA

OMICS International also took the privilege of felicitating Flu-2015, Chair and Co-Chairs whose support made conference a great success.
Pamuk Bilsel, FluGen, Inc, USA
Masayuki Noguchi, Hokkaido University, Japan
Rob Lambkin-Williams, hVIVO, UK
Benicio Gutiérrez-Doña, Universidad Estatal a Distancia, Costa Rica

For enjoy and sharing the memories about conference kindly follow the link: Flu-2015 Gallery

To continue our engagement against influenza and to be prepared for the next outbreak we need further global efforts to understand viral mechanisms, host-pathogen interactions and immunological pathways. OMICS International welcome all the 2nd International Conference on Flu during October 31- November-02 2016, at San Francisco, USA. We invite all the eminent researchers, students and delegate participants to take part in this upcoming conference to witness invaluable scientific discussions and contribute to the future innovations in the field of Influenza research.

Let us [email protected] Flu-2016

Past Reports Gallery

Flu-2016

Conference series llc LTD hosted the “2^nd International Conference on Flu” during October 31-November 02, 2016 at DoubleTree by Hilton Hotel San Francisco Airport, San Francisco, USA with the theme “Scientific Milestones in Understanding and Preventing Flu” where eminent keynote speakers from various reputed institutions and organizations with their resplendent presence addressed the gathering.

Benevolent response and active participation was received from the renowned experts and Editorial Board Members of Conference series Journals as well as from the Immunologists, Virologists, scientists, researchers, students and leaders in Flu Research, who made this event successful.

The Conference was carried out through various informative and cutting edge sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

Flu Vaccines: Current and Novel Approach
Pathology of Influenza Virus Infections
Flu Symptoms & Treatment
Antivirals and Therapeutics
Flu Vaccines and Vaccination: Opportunities and Challenges for All Age Groups
Flu Virus -Advancements in Detection & Differentiation
Flu: Immunology & Genetics
Flu Clinical Studies & Case Reports
Epidemiology and Public Health of Influenza
Surveillance Issues and Burden of Disease

The conference was embarked with an opening ceremony followed by a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

Notable Keynotes:

Donald P Francis, Global Solutions for Infectious Diseases, USA
Ananda M Chakrabarty, University of Illinois College of Medicine, USA
Anthony S Gilbert, hVIVO, UK
Palayakotai Raghavan, Nanorx Inc, USA
Manon M J Cox, Protein Sciences, USA
Phillip Bertrand Berkey Moheno, SanRx Pharmaceuticals Inc; USA
Sunil K Lal, Monash University, Malaysia

All the above mentioned Honorable Guests and Keynote speakers gave their energetic and fruitful contributions and special thanks to our Honorable Moderator Jun Wang, University of Arizona, USA and Sunil K Lal, Monash University, Malaysia for his remarkable contribution towards smooth functioning at Flu-2016 Conference.

Conference Sessions Chairs:

Donald P Francis, Global Solutions for Infectious Diseases, USA
Palayakotai Raghavan, Nanorx Inc, USA
Phillip Bertrand Berkey Moheno, SanRx Pharmaceuticals Inc; USA

For further information visit : Flu 2016

Conference Series llc LTD offers its heartfelt appreciation to Societies and Organizations includes Allied Academies, Andrew John Publishing Inc., New York Private Equity Forums and is also obliged to the Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with Conference series llc LTD in supporting and making the conference a never before one.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph Flu-2016, Conference Series LLC is delighted to announce the next event. Mark your calendars for the upcoming extravaganza, "3^rd International Conference on Flu & Emerging Infectious Diseases" to be held during September 17-18, 2018 at San Diego, USA.

Let us meet again @ Flu-2018

Past Reports Gallery

Infectious Diseases 2015

Sensing the raising importance of Infectious Diseases prevention, control, treatment and cure, OMICS International hosted the World Congress on Infectious Diseases (Infectious diseases 2015), scheduled from August 10-12, 2015 in London, UK with a theme “Novel technologies and innovations for prevention and treatment of "infectious diseases”. The conference was successful in gathering eminent speakers from various reputed organizations and their paramount talks enlightened the gathering.

The pragmatic meet organized by OMICS International received generous response from the Editorial Board Members of OMICS Group Journals as well as expertise from academia, talented researchers and young student community. Researchers and students who attended from different parts of the world made the conference one of the most successful and productive events in 2015 from OMICS Group. The conference was marked with the presence of renowned Speakers, Young Researchers, Students and Business Delegates driving the three day event into the path of success with thought provoking keynote and plenary presentations.

The meeting was carried out through various sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

Global Trends in Emerging Infectious Diseases
Microbial Pathogenesis and Virulence
Immunology of Infections
Mechanism of Resistance
Noscomial Infections
Infectious Diseases in Animals
Rapid Assessment Diagnostic Methods
Therapeutic Agents and Therapeutic Measures
Ebola and Current Research
Epidemiology of Emerging and Re emerging diseases
Plant Disease Modelling and Parameter Estimation
Ebola and Current Research
Common Infectious Diseases
Infectious Diseases in Pregnancy
Tropical Infectious Diseases
Communicable and Contagious Infectious Diseases
Public Awareness

The conference was embarked with an opening ceremony followed by Keynote presentations, Special sessions, Workshop and a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

Workshop

Title: “The threat of zoonotic diseases and Ebola virus disease specifically”

Dr. Stef Stienstra, Dutch Armed Forces / Royal Dutch Navy, Netherlands

Keynote Presentations

Dr. M. Khalid Ijaz, RB, USA

Dr. Guido Norbiato, University Hospital L. Sacco, Italy

Dr. Stef Stienstra, Dutch Armed Forces / Royal Dutch Navy, Netherlands

Dr. Janet Hammond, Roche Pharma Research and Early Development, Switzerland

Dr. Ashok Kapse, Mahavir Super Specialty Hospital, India

Special Sessions

Dr. Irina Magdalena Dumitru, Ovidius University Constanta, Romania

Dr. Stef Stienstra, Dutch Armed Forces / Royal Dutch Navy, Netherlands

Young Researchers

Title: “Phylogenetic and phylogeographic mapping of the avian coronavirus in wild and synanthropic birds”

Ricardo Durães-Carvalho, Massachusetts Institute of Technology, USA

Title: “The promising rule of neutrophil cd64 as an early diagnostic and prognostic marker in neonatal sepsis”

Shereen Ahmed El Masry, Ain Shams University, Egypt

Title: “The predictive and prognostic values of neutrophil cd64, neutrophil cd11b, monocyte cd14 and presepsin in neonatal sepsis”

Heba Ezzat Hashem, Ain Shams University, Egypt

Title: “Irrational antibiotics prescribing behaviour of physicians in Taiwan”

Usman Iqbal, Taipei Medical University, Taiwan

Title: “Quality of life amongst HIV and tuberculosis patients”

Anshu Kumar Jha, Kasturba Medical College, India

Best Poster Awards

Matougui Nada, University of Angers, France

Himani B. Pandya, S.B.K.S Medical College, India

Best Young Researcher Award

Shereen Ahmed El Masry, Ain Shams University, Egypt

OMICS International offers its heartfelt appreciation to Societies and Organizations, Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with OMICS International in supporting and making the conference a grandiose event.

Your rejoinder is our inspiration; keeping this motto in mind and being witnessed the triumph of Infectious Diseases 2015, OMICS International is delighted to announce the next event, "2^nd World Congress on Infectious Diseases" to be held during August 25-27, 2016 Philadelphia, USA.

Let us meet again @ Infectious Disease 2016

Past Reports Gallery

Infectious Diseases 2016

Infectious Diseases 2016 Past Conference Report

Sensing the raising importance of Infectious Diseases prevention, control, treatment and cure, Conference Series LLC hosted 2^nd World Congress on Infectious Diseases (Infectious Diseases 2016), scheduled from August 24-26, 2016 in Philadelphia, USA with a theme “Fighting Infectious Diseases with Novel and Innovative Therapeutic Techniques”. The conference was successful in gathering eminent speakers from various reputed organizations and their paramount talks enlightened the gathering.

The pragmatic meet organized by Conference Series LLC received generous response from the Editorial Board Members of Conference Series LLC Journals as well as expertise from academia, talented researchers and young student community. Researchers and students who attended from different parts of the world made the conference one of the most successful and productive events in 2016 from Conference Series LLC. The conference was marked with the presence of renowned Speakers, Young Researchers, Students and Business Delegates driving the three day event into the path of success with thought provoking keynote and plenary presentations.

The meeting was carried out through various sessions, in which the discussions were held on the following thought provoking and cerebrating scientific tracks:

· Infectious Diseases

· Global Trends in Emerging Infectious Diseases

· Microbial Pathogenesis and Virulence

· Ebola and Current Research

· Pediatric Infectious Diseases

· Immunology of Infections

· Epidemiology of Emerging and Re Emerging Diseases

· Diagnosis of Infectious Diseases

· Treatment for Infectious Diseases

· Infectious Diseases Prevention, Control Measures and Cure

· Clinical Studies and Case Reports

· Mechanism of Resistance

· Tuberculosis

· Hepatitis

· Antibiotic Resistance

Infectious Diseases 2016 Proceedings

The conference was embarked with an opening ceremony followed by Keynote presentations, Workshop and a series of lectures delivered by both Honourable Guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

1. Moderators

· Dr. Stef Stienstra, Dutch Armed Forces / Royal Dutch Navy, Netherlands

· Dr. Ashok Kapse, Mahavir Super Specialty Hospital, India

2. Session Chairs

· Dr. Glenn S Tillotson, Cempra Pharmaceuticals, USA

· Dr. Joanna Zajkowska, Medical University of Białystok, Poland

· Dr. Francis J Castellino, University of Notre Dame, USA

· Dr. Eugenie Bergogne-Berezin, Centre Hospitalo-Universitaire Bichat-Claude Bernard University Diderot, France

· Dr. Stef Stienstra, Dutch Armed Forces / Royal Dutch Navy, Netherlands

· Dr. Rachel Groppo, Sanofi Pasteur, USA

3. Poster Judges

· Dr. Stef Stienstra, Dutch Armed Forces / Royal Dutch Navy, Netherlands

· Dr. Maria Luisa G Daroy, St. Luke’s Medical Center, Philippines

4. Keynote Presentations

· Glenn S Tillotson, Cempra Pharmaceuticals, USA

· Rachel Groppo, Sanofi Pasteur, USA

· Thomas D Licker, Decontamination Professionals International, Infection Control Technologies, USA

· Stef Stienstra, Dutch Armed Forces / Royal Dutch Navy, Netherlands

· Francis J Castellino, University of Notre Dame, USA

· Joanna Zajkowska, Medical University of Białystok, Poland

· Eugenie Bergogne-Berezin, Centre Hospitalo-Universitaire Bichat- Claude Bernard University Diderot, France

· Ashok Kapse, Mahavir Super Specialty Hospital, India

· Lalit Garg, University of Malta, Malta

· K C Santosh, University of South Dakota, USA

5. Workshop

Title: “Dengue diagnosis and case management”

Dr. Ashok Kapse, Mahavir Super Specialty Hospital, India

6. Young Researchers Forum

Title: “Investigation of the role of the sRNA RyhB in regulating the locus of enterocyte effacement pathogenicity Island in enteropathogenic Escherichia coli”

Marisa Egan, Saint Joseph’s University, USA

Title: “Leprosy and medical practitioners in Enugu, Southern Nigeria”

Otache Adah Emmanuel, University of Nigeria, Nigeria

7. Best Poster Awards

· Title: Recurrent cardiac tamponade secondary to coxsackie B type 4

Moamen AL Zoubi, Advocate Illinois Masonic Medical Center, USA

· Title: Pediatric gastrointestinal basidiobolomycosis

Mojdeh Habibi Zoham, Tehran University of Medical Sciences, Iran

Conference Series LLC offers its heartfelt appreciation to Societies and Organizations, Organizing Committee Members, adepts of field, various outside experts, company representatives and other eminent personalities who interlaced with Conference Series LLC in supporting and making the conference a grandiose event.

Your rejoinder is our inspiration, keeping this motto in mind and being witnessed the triumph of Infectious Diseases 2016, Conference Series LLC is delighted to announce the next event, "3^rd Annual Congress on Infectious Diseases" to be held during August 21-23, 2017, San Francisco, California, USA.

Let us meet again @ Infectious Disease 2017

Past Reports Gallery

Infectious Diseases 2017

Sensing the raising importance of infectious diseases prevention, control, treatment and cure, Conference Series LLC hosted 4th International Congress on Infectious Diseases (Infection Congress 2017), during May 11-12, 2017 in Barcelona, Spain with the theme “Exploring recent outbreaks, advances and technologies in treatment and research of infectious diseases”. The conference was successful in gathering eminent speakers from various reputed organizations and their paramount talks enlightened the gathering. The pragmatic meet organized by Conference Series LLC received generous response from the Editorial Board Members of the Journals as well as expertise from Academia, Talented Researchers and Young Student Community. Researchers and students who attended from different parts of the world made the conference one of the most successful and productive event. The conference was marked with the presence of Renowned Speakers, Young Researchers, Students and Business Delegates driving the two day event into the path of success with thought provoking keynote and plenary presentations.

The Infection Congress-2017 Conference was carried out through various sessions with discussions on the following thought provoking major scientific tracks:

· Infection and Immune System

· Host and Microbial Genetics

· Infections from Contaminated Pharmaceuticals or Counterfeit Medications

· Foodborne and Waterborne Illnesses

· Emergence and Pathogenesis of Coronaviruses

· Nosocomial Infections

· Pediatric Infections

· Hemorrhagic Fevers

· New or Rapid Diagnostics

· Therapeutic Interventions in Rare Diseases

· Antimicrobial Resistance

· Infection Control and Epidemiology

· Drug Metabolism in Microorganisms

· New Opportunities for Tuberculosis Control

Infection Congress 2017 Proceedings

· Key Note Forum

· Tracks

· Posters and Accepted Abstracts

The conference was embarked with an opening ceremony followed by Keynote presentations, Workshop and a series of lectures delivered by both honorable guests and members of the Keynote forum. The adepts who promulgated the theme with their exquisite talk were:

1. Moderators

Vaneza Leah Espino, UP-Philippine General Hospital, Philippines

2. Session Chairs

· Dr. Imran Khan, University of California, Davis, USA

· Walter Fierz, Labormedizinisches zentrum Dr Risch, Liechtenstein

3. Poster Judges

· Dr. Imran Khan, University of California, Davis, USA

· Dr. Ashok Rattan, Pathkind Diagnostics Pvt Ltd, New Delhi, India

4. Keynote Presentations

· Dr. Ashok Rattan, Pathkind Diagnostics Pvt Ltd, New Delhi, India

· Dr. Imran Khan, University of California, Davis, USA

5. Workshop

· Workshop on “Nitrofurantoin Sensitivity Pattern PAN India of Uropathogens” by Ashok Rattan, Pathkind Diagnostics Pvt Ltd, New Delhi, India

6. Young Researchers Forum

· Hailay Gesesew, Flinders University, Australia

· Ambak Kumar Rai, Motilal Nehru National Institute of Technology, India

· Oscar Guanya, Busia County Referral Hospital, Kenya

7. Best Poster Awards

Conference Series LLC offers its heartfelt appreciation to Societies and Organizations and is obliged to the Organizing Committee Members, Adepts of Field, Various Outside Experts, Company Representatives and other eminent personalities who interlaced with Conference Series LLC in supporting and making the conference a grandiose event.

Your rejoinder is our inspiration, keeping this motto in mind and being witnessed the triumph of Infection Congress 2017, Conference Series LLC is delighted to announce the next event, “11th World Congress on Infectious Diseases” to be held during July 23-25, 2018 Melbourne, Australia.

Let us meet again @ Infectious Diseases Congress 2018

Past Reports Gallery